rs10947690 — MDGA1 Leu61Pro

MDGA1 Leu61Pro — The Inhibitory Synapse Gate and Sleep

Deep sleep depends on the brain's ability to quiet itself. That quieting is controlled by GABAergic neurons¹¹ GABAergic neurons
Inhibitory neurons that release gamma-aminobutyric acid (GABA), the brain's primary inhibitory neurotransmitter, to reduce neural excitability — and the precise assembly of their synapses is governed by a molecular handshake between two proteins: neuroligin-2 (NL2) and neurexin. MDGA1 (MAM Domain Containing Glycosylphosphatidylinositol Anchor 1) acts as a gatekeeper that regulates this handshake, and the rs10947690 Leu61Pro variant shifts the balance in a direction that weakens GABAergic signaling and, in large-scale human genetics studies, reliably increases the risk of chronic insomnia.

The Mechanism

Inhibitory synapses form when neuroligin-2 (on the postsynaptic membrane) binds to neurexin²² neurexin
A presynaptic adhesion protein that anchors the synapse and recruits the GABA release machinery on the sending neuron on the presynaptic side. MDGA1 binds NL2 through three contact interfaces and physically blocks the neurexin-binding site, preventing the trans-synaptic adhesion required for inhibitory synapse formation.

The 2017 crystal structure study³³ 2017 crystal structure study
Kim JA et al. Structural Insights into Modulation of Neurexin-Neuroligin Trans-synaptic Adhesion by MDGA1/Neuroligin-2 Complex. Neuron, 2017 showed that all three MDGA1-NL2 contact points are required for full suppression of synaptogenic activity, and that MDGA1 selectively targets NL2 (the inhibitory-synapse neuroligin) rather than NL1 (the excitatory-synapse neuroligin). This selectivity means MDGA1 is a dedicated brake on inhibitory circuit assembly.

The Leu61Pro substitution falls in the immunoglobulin domain 1 (Ig1) of MDGA1, one of the three contact interfaces. Proline introduces a rigid kink in the protein backbone that destabilizes the Ig1 fold. A structurally perturbed Ig1 domain has reduced affinity for NL2 — meaning the MDGA1 brake becomes hyperactive, or alternatively, the protein adopts an aberrant conformation that interferes with normal NL2 trafficking. Either outcome reduces functional inhibitory synapse density.

A 2025 study in the lateral habenula⁴⁴ 2025 study in the lateral habenula
Wang et al. Chronic stress induces depression through MDGA1-Neuroligin2 mediated suppression of inhibitory synapses in the lateral habenula. Theranostics, 2025 showed that elevated MDGA1-Nlgn2 interaction suppresses GABAergic synapse density; blocking this interaction increased inhibitory transmission and conferred resistance to stress-induced depressive behavior. This convergent evidence supports the model that rs10947690-G, by disrupting normal MDGA1 structure, perturbs the inhibitory synapse set-point in brain circuits regulating sleep and arousal.

The Evidence

The strongest evidence comes from two landmark 2019 GWAS studies published simultaneously in Nature Genetics.

Jansen et al. (2019)⁵⁵ Jansen et al. (2019)
Jansen PR et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nature Genetics, 2019 — the largest insomnia GWAS to date — identified rs10947690-G as a genome-wide significant insomnia locus (OR 1.048, p = 4×10⁻¹²), with a sex-stratified female analysis also reaching significance (OR 1.049, p = 2×10⁻⁸). The 202 loci identified explained 2.6% of the variance in insomnia, with enrichment in striatal, hypothalamic, and claustrum neurons — all regions involved in sleep-wake regulation.

Lane et al. (2019)⁶⁶ Lane et al. (2019)
Lane JM et al. Biological and clinical insights from genetics of insomnia symptoms. Nature Genetics, 2019 independently identified 57 insomnia loci across 453,379 UK Biobank participants and validation cohorts totaling over 160,000 additional individuals. Both studies found enrichment in ubiquitin-mediated proteolysis pathways and multiple brain region expression signatures consistent with the synaptic regulation hypothesis.

Watanabe et al. (2022)⁷⁷ Watanabe et al. (2022)
Watanabe K et al. Genome-wide meta-analysis of insomnia prioritizes genes associated with metabolic and psychiatric pathways. Nature Genetics, 2022 extended the analysis to 2.4 million individuals, identifying 554 risk loci. Gene prioritization among 3,898 candidates highlighted synaptic signaling and neuronal differentiation as the primary functional pathways — consistent with MDGA1's role.

Hatcher et al. (2019)⁸⁸ Hatcher et al. (2019)
Hatcher C et al. Leveraging brain cortex-derived molecular data to elucidate epigenetic and transcriptomic drivers of complex traits and disease. Translational Psychiatry, 2019 used Bayesian colocalization of prefrontal cortex gene expression, DNA methylation, and histone acetylation data with GWAS summary statistics, identifying MDGA1 as a novel locus where the same genetic variant influences both brain gene expression and insomnia susceptibility — strengthening the case for a functional, brain-expressed mechanism.

Practical Actions

GABAergic signaling tone can be supported through several nutritional strategies. Magnesium acts as an NMDA receptor antagonist and GABA modulator⁹⁹ NMDA receptor antagonist and GABA modulator
Magnesium blocks NMDA (excitatory glutamate) receptors and potentiates GABA-A receptor activity, effectively supporting inhibitory tone and has demonstrated sleep improvements in controlled trials — specifically increasing slow-wave sleep and reducing nocturnal cortisol. Glycine, at 3 g before bed, activates NMDA receptors in the suprachiasmatic nucleus to promote sleep onset and has shown reductions in sleep fragmentation in human trials. Taurine potentiates GABA-A and GABA-B receptors and modulates inhibitory tone.

For rs10947690-G carriers, these interventions address the downstream consequence of reduced inhibitory synapse density: insufficient GABAergic tone at the point of sleep onset.

Interactions

MDGA1's role in GABAergic signaling connects it functionally to other sleep-related pathways. GABAergic tone interacts with cortisol rhythms (HPA axis variants like FKBP5, CRHR1) and with circadian regulation (CLOCK, CRY1, PER3 variants). Individuals carrying both MDGA1 Leu61Pro and circadian variants such as rs1801260 (CLOCK) or rs57875989 (CRY1) may experience compounding insomnia susceptibility from two independent pathways — reduced inhibitory synapse density from MDGA1 and disrupted circadian timing from clock gene variants. No published compound genotype data exist, but the pathway logic is robust.